Rethinking treatment for nervous system disorders
Empowering patients to live on their own terms
Who We Are
At its core, Eliem is motivated by the promise of helping people live happier, more fulfilling lives. The Eliem team channels its experience, energy and passion for improving patients’ quality of life by developing life-changing novel therapies for neuronal excitability disorders based on clinically validated mechanisms of action.
Our Approach: Optimizing Treatments for Neuronal Excitability Disorders
Tens of millions of people suffer from central and peripheral nervous system disorders, where an imbalance between excitation and inhibition has disrupted the homeostasis in affected neuronal networks. These disorders include a range of common conditions such as chronic pain, depression, epilepsy and anxiety. Currently available treatments for these conditions often fail to provide adequate control or relief, and they are often poorly tolerated, leaving people unable to live life on their own terms.
Developing improved treatments for patients requires a pragmatic and diligent approach. Equal parts rigorous and agile, the experienced Eliem team strives to make treatments that are more effective, safer and better tolerated than currently available treatments. Leveraging clinically validated mechanisms of action, we are moving steadily and efficiently to develop novel therapeutics for neuronal excitability disorders that deliver enhanced outcomes for patients.
Our Pipeline
Our clinical and preclinical pipeline is focused on neuronal excitability conditions of the central and peripheral nervous system. We are developing ETX-155 for major depressive disorder and focal onset seizures. This compound is designed to dramatically improve on the limitations of existing therapies with the potential to be best-in-class for these conditions with high unmet clinical needs.
Our Experienced Team
Eliem is founded and led by a team of seasoned industry executives who collectively bring decades of clinical development and biopharmaceutical commercialization experience to the company. The team not only shares an unparalleled determination and passion to help patients, but they also have a history of working together to successfully build companies and bring novel and effective therapies to market. Eliem is also advised by a Board with considerable neurology research and development experience and a strong track record of building successful companies.
The team’s combined expertise in neurological research, clinical development, commercialization and company building are critical for delivering on the promise of bringing innovative therapies to market to provide relief and hope for the millions of patients affected by neurological conditions.
The team’s combined expertise in neurological research, clinical development, commercialization and company building are critical for delivering on the promise of bringing innovative therapies to market to provide relief and hope for the millions of patients affected by neurological conditions.
Leadership Team
Board of Directors
Bob Azelby
President and Chief Executive Officer
Bob Azelby
President and Chief Executive Officer
Bob most recently served as the President and CEO of Alder BioPharmaceuticals, a clinical-stage biopharmaceutical company that was acquired by H. Lundbeck for $2.3 billion in 2019. Previously, he was Juno Therapeutics’ Executive Vice President and Chief Commercial Officer, participating in the management of all aspects of Juno’s operations and accountable for leading and developing Juno’s commercial capabilities. Juno was acquired by Celgene for $9 billion in 2018. Prior to Juno, Bob was the Vice President and General Manager of Amgen’s US Oncology Business Unit, responsible for $6.5 billion annual net revenue. Over his 15-year career with Amgen, Bob held numerous sales and marketing positions, including Vice President of US Oncology Sales, Vice President of North American Commercial Operations, General Manager for Amgen Netherlands and Senior Marketing Director. He is currently a member of the Clovis Oncology Board of Directors and was formerly on the Immunomedics and Cascadian Therapeutics Board of Directors. Bob received his undergraduate degrees in economics and religious studies from the University of Virginia and his master of business administration from Harvard University.
Valerie Morisset, Ph.D.
Executive Vice President, R&D and Chief Scientific Officer
Valerie Morisset, Ph.D.
Executive Vice President, R&D and Chief Scientific Officer
Valerie is Co-Founder and Chief Scientific Officer of Eliem Therapeutics. Valerie has more than 20 years’ experience in the pharmaceutical industry, with positions of increasing responsibility at Novartis, GSK, Convergence and Biogen. Prior to joining Eliem, Valerie was a founding venture partner at Bridge Valley Ventures. She co-founded Convergence Pharmaceuticals, where she established and led the Biology and Translational Medicine team, and she was instrumental in the sale of Convergence to Biogen for $675M in 2015. Valerie subsequently joined Biogen in a senior leadership role. She has worked extensively in the field of drug development for pain and across a number of other therapeutic areas including neurology, psychiatry, gastrointestinal disorders and sensory biology. Valerie trained as an electrophysiologist and completed her doctorate at the University of Bordeaux.
Erin Lavelle
Executive Vice President, Chief Operating Officer & Chief Financial Officer
Erin Lavelle
Executive Vice President, Chief Operating Officer & Chief Financial Officer
Erin has more than 20 years of cross-functional experience leading strategic and operational initiatives in the biopharmaceutical industry. Erin was Chief Operating Officer of Alder BioPharmaceuticals, leading the company’s readiness for launch of its first therapy, including enterprise planning around supply chain, compliance and information technology. She led the company’s $2.3 billion sale to H. Lundbeck in 2019. Prior to Alder, Erin worked at Amgen for 15 years in a variety of roles in the corporate development, finance and commercial organizations. Her most recent role was General Manager of Amgen Taiwan, where she managed a portfolio of six commercialized products. Erin worked in Hong Kong as an Executive Director for the Japan Asia-Pacific region during its initial build. She began her career as an investment banker focused on biotech M&A and financing in the healthcare group at Merrill Lynch & Co. Erin is currently a member of the Neoleukin Therapeutics Board of Directors and serves as President of the Seattle chapter of the Healthcare Businesswomen’s Association (HBA). She holds a bachelor of arts in economics from Yale University.
James Bucher, J.D.
Executive Vice President & General Counsel
James Bucher, J.D.
Executive Vice President & General Counsel
Jim served as Executive Vice President and General Counsel of Alder BioPharmaceuticals, a clinical-stage biopharmaceutical company that was acquired by H. Lundbeck for $2.3 billion in 2019. Jim was a standing member of Alder’s Executive Team, participating in the management of all aspects of Alder’s strategy and operations, with direct responsibility for the company’s legal affairs, intellectual property, risk management, and compliance. Prior to joining Alder, Jim was Vice President of Corporate Legal Affairs and Secretary as well as the Corporate Compliance Officer of Exelixis, a NASDAQ-listed biopharmaceutical company. He was a partner at the international law firm Shearman & Sterling LLP, serving with the firm for 16 years. Jim has significant experience with capital raising, including execution of six equity and convertible debt financings generating over $900 million in capital for Alder and eight equity and debt financings generating over $1 billion in capital for Exelixis. Jim holds a juris doctorate with distinction from Emory University School of Law and a bachelor of arts in biology from Colgate University.
Mark Versavel, M.D., Ph.D., MBA
Interim Chief Medical Officer
Mark Versavel, M.D., Ph.D., MBA
Interim Chief Medical Officer
Dr. Versavel joined Eliem as SVP, Clinical Development in March 2021 and was appointed Interim Chief Medical Officer in January 2022. Mark has over 30 years of clinical development experience in neuropathic pain and multiple neurology and psychiatry indications across the areas of clinical pharmacology, early and late phase clinical trials and support of marketed products. Mark is the founder and President of the life science consulting firm vZenium LLC, and prior to joining Eliem served as Chief Medical Officer at Alzheon, Inc., Neurobo Pharmaceuticals, and Cavion Pharma. Earlier in his career, Mark held positions of increasing responsibility in clinical research at Bayer AG, Schering AG, Parke Davis / Pfizer, Sepracor / Sunovion and Zalicus. During his career Mark has led late stage development and medical affairs activities for pregabalin (Lyrica) in neuropathic pain and epilepsy, ziprasidone (Geodon) in schizophrenia and bipolar depression, eszopiclone (Lunesta) in sleep disorders, and eslicarbazepine acetate (Aptiom) in epilepsy.
Mark received his M.D. from University of Antwerp, Belgium, Ph.D. (Dr. Med.) in clinical pharmacology from Humboldt University in Berlin, Germany and MBA from University of Michigan.
Mark received his M.D. from University of Antwerp, Belgium, Ph.D. (Dr. Med.) in clinical pharmacology from Humboldt University in Berlin, Germany and MBA from University of Michigan.
Jo Palmer-Phillips, Ph.D.
Chief Development Officer
Jo Palmer-Phillips, Ph.D.
Chief Development Officer
Jo is a neuropsychologist with over 18 years’ experience working in clinical development in the pharmaceutical industry with a focus on pain and migraine. She has held positions in both clinical operations and clinical strategy including leading multidisciplinary clinical teams at Roche, GSK, Convergence Pharmaceuticals and Biogen. Jo was a founding member of Convergence Pharmaceuticals Ltd and a member of the leadership team. As the Head of Clinical Operations at Convergence, she was responsible for designing and managing the full-service outsourcing of phase 1 and 2 clinical studies in pain. She was also responsible for establishing and maintaining the Quality System.
Susan Franks, MS
Senior Vice President/Head of Regulatory Affairs
Susan Franks, MS
Senior Vice President/Head of Regulatory Affairs
Susan brings over 30 years of experience in regulatory affairs, with a focus on pain and CNS therapies Prior to joining Eliem, she most recently served as the Senior Vice President and Head of Regulatory Affairs at Braeburn Inc., where she was responsible for managing the regulatory team across all CMC, clinical, and non-clinical operations and promotional functions with a focus on its opioid use disorder (OUD) and pain pipeline. Previously, she managed global regulatory affairs at Teva Pharmaceuticals, Cephalon, Premier Research Group, and Wyeth Pharmaceuticals. Over the course of her career, Susan led the successful registration of Exalgo® (hydromorphone extended release) and Vantrela® ER (hydrocodone), the tentative approval for Brixadi™ (buprenorphine extended-release) as well as leading several successful FDA Advisory Committees. Susan holds a BS in Chemistry from Clarkson University and an MS in Chemistry from Lehigh University.
Andrew Levin, M.D., Ph.D.
(Chairman)
Andrew Levin, M.D., Ph.D.
(Chairman)
Andrew is a Co-Founder of Eliem Therapeutics and Chairman of the Board of Directors. In addition to co-founding Eliem, Andrew spearheads drug discovery efforts at RA Capital Management, L.P. that have led to the formation of several companies and serves as a Managing Director on the Investment Team. Previously, Andrew was a Vice President at H.I.G. BioVentures, and prior to that he served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. He holds a bachelor of science in mechanical engineering from Princeton University, a doctorate in biomedical engineering from the Massachusetts Institute of Technology and a medical degree from Harvard Medical School.
Bob Azelby
Bob Azelby
Bob most recently served as the President and CEO of Alder BioPharmaceuticals, a clinical-stage biopharmaceutical company that was acquired by H. Lundbeck for $2.3 billion in 2019. Previously, he was Juno Therapeutics’ Executive Vice President and Chief Commercial Officer, participating in the management of all aspects of Juno’s operations and accountable for leading and developing Juno’s commercial capabilities. Juno was acquired by Celgene for $9 billion in 2018. Prior to Juno, Bob was the Vice President and General Manager of Amgen’s US Oncology Business Unit, responsible for $6.5 billion in annual net revenue. Over his 15-year career with Amgen, Bob held numerous sales and marketing positions including Vice President of US Oncology Sales, Vice President of North American Commercial Operations, General Manager for Amgen Netherlands, Senior Marketing Director, etc. He is currently a member of the Clovis Oncology Board of Directors and was formerly on the Immunomedics and Cascadian Therapeutics’ Board of Directors. Bob received his undergraduate degrees in economics and religious studies from the University of Virginia and his master of business administration from Harvard University.
Judith Dunn, Ph.D.
Judith Dunn, Ph.D.
Judy is the President and Head of R&D at Fulcrum Therapeutics. Prior to this role, Judy was an Entrepreneur-in-Residence at Atlas Venture, where she focused on new company creation. Previously, Judy served as Vice President and Global Head of Clinical Development at Roche in Basel, Switzerland, and Head of the Roche Innovation Center in NYC. She has held leadership positions in both the research and commercial neuroscience divisions of Pfizer and in clinical psychiatry at Sepracor. Judy is currently an independent board director at Evolution Research Group and a member of the NYC Mayor’s Advisory Council on Life Sciences. She has also served as a scientific advisor to the Tri-Institutional Therapeutics Discovery Institute and as a board member of the Partnership for NY Fund.
Leone Patterson
Leone Patterson
Leone is chief financial and business officer of Tenaya Therapeutics, where she leads corporate finance, investor relations, corporate communications, strategy and business development, as well as other operational functions. She has over 20 years of experience in the biotechnology industry. Prior to Tenaya, Leone served as President and Chief Financial Officer of Adverum Biotechnologies, and previously held the positions of CEO and Director. Prior to Adverum, she was Chief Financial Officer at both Diadexus and Transcept Pharmaceuticals. She also held senior finance positions at Exelixis, Novartis, and Chiron. Leone began her career at KPMG working in the firm’s audit practice. She earned a bachelor of science in business administration and accounting from Chapman University and an executive master of business administration from St. Mary’s College. She is also a Certified Public Accountant (inactive status). She currently serves on the board of directors for Nkarta, Inc.
Liam Ratcliffe, M.D., Ph.D.
Liam Ratcliffe, M.D., Ph.D.
Liam is the head of Access Biotechnology, the strategic investment arm specializing in therapeutic platforms and products at Access Industries. Prior to his work at Access Industries, he was Managing Director at New Leaf Venture Partners, where he concentrated on biopharmaceutical investing. Prior to joining New Leaf in 2008, Liam served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Midwest region (based in Ann Arbor, Mich.) and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. He received his medical degree and doctorate in immunology from the University of Cape Town and his master of business administration from the University of Michigan. He completed his internal medicine training and fellowship in immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.
Adam Rosenberg
Adam Rosenberg
Adam is a Venture Partner at RA Capital Management. Adam currently serves on other private company boards and is Chair of Ambagon Therapeutics. Adam was most recently President, CEO and member of the Board of Directors of Rodin Therapeutics until its acquisition by Alkermes in 2019. Adam has 20+ years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Adam was also an advisor and investor in “A Late Quartet”, an entrepreneurial feature film centered on a cellist diagnosed with Parkinson’s disease, starring Philip Seymour Hoffman, Catherine Keener and Christopher Walken. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College.
Simon Tate
Simon Tate
Simon is a Managing Director at Intermediate Capital Group (ICG) and has 30 years of experience in R&D. He has spent most of his career working in the fields of Pain and Neuroscience. He was one of the founders of Convergence Pharmaceuticals, and as Chief Scientific Officer and head of R&D, he led Convergence to its successful acquisition by Biogen for $675M in 2015. Following this acquisition, Simon joined Biogen, where he assumed the role of Vice President and Head of the Pain Therapeutic Area. Prior to Convergence, Simon was Vice President and Head of Pain, Epilepsy, and Migraine drug discovery and early development in GSK, where he held senior roles in Neurology, Psychiatry, and Discovery Sciences during his 20-year career. Originally trained as a Biochemist, Simon graduated from the University of Dundee, where he had the privilege to work with Sir Philip Cohen, who was, at the time, the world’s third most cited professor.
News
Eliem Therapeutics Provides ETX-810 Program Update
Phase 2a clinical trial of ETX-810 in lumbosacral radicular pain (LSRP) did not achieve the primary endpoint; ETX-810 program will be discontinued SEATTLE and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics , Inc. (Nasdaq: ELYM), a clinical-stage biotechnology
Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder
Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023 Sufficient capital expected to fund operations until mid-2024 SEATTLE and CAMBRIDGE, United Kingdom, July 18, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics , Inc.
Load More
08/02/2022
Phase 2a clinical trial of ETX-810 in lumbosacral radicular pain (LSRP) did not achieve the primary endpoint; ETX-810 program will be discontinued SEATTLE and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics , Inc. (Nasdaq: ELYM), a clinical-stage biotechnology
07/18/2022
Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023 Sufficient capital expected to fund operations until mid-2024 SEATTLE and CAMBRIDGE, United Kingdom, July 18, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics , Inc.
07/07/2022
SEATTLE and CAMBRIDGE, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
06/27/2022
Topline data from the Phase 2a clinical trial are expected in the third quarter of 2022 Virtual investor event to be held in July 2022 SEATTLE and CAMBRIDGE, United Kingdom, June 27, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing
05/16/2022
SEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
04/25/2022
Phase 2a clinical trial of ETX-810 in diabetic peripheral neuropathic pain (DPNP) did not achieve the primary endpoint Phase 2a clinical trial evaluating ETX-810 in patients with lumbosacral radicular pain (LSRP) has been fully enrolled with topline data anticipated in the third quarter of 2022
04/05/2022
SEATTLE and CAMBRIDGE, United Kingdom, April 05, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
03/21/2022
SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
03/07/2022
Completed dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be presented in 1H 2022 Interim data from Phase 1b clinical trial of ETX-155 in subjects with photosensitive epilepsy to be presented in 1H 2022 Submitted Investigational
03/06/2022
By Bob Azelby
More restrictive opioid prescribing guidelines were put in place in a rightful effort to stop a devastating crisis. But this sudden and dramatic change negatively impacted chronic pain patients who were managing their pain through prescription opioids given few other effective options.
02/11/2022
SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
02/07/2022
SEATTLE and CAMBRIDGE, United Kingdom, Feb. 07, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
01/18/2022
ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) is fully enrolled Investigational New Drug (IND) application planned in Q1 2022 for ETX-155 Phase 2 trials in major depressive disorder (MDD) and perimenopausal depression (PMD) Patient dosing underway for ETX-155 Phase 1b
11/08/2021
Advanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant progress made toward the initiation of major depressive disorder (MDD) and perimenopausal depression (PMD) clinical trials Continued to enroll ETX-810’s two
11/04/2021
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 04, 2021 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the
09/13/2021
On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross proceeds that, along with existing cash, provides cash runway through late 2023 SEATTLE and CAMBRIDGE,
08/13/2021
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (NASDAQ: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central
08/10/2021
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the
05/24/2021
Advances two clinical programs through topline data across four indications Progresses two preclinical programs to potential lead candidate selection Brings total funding since inception to $140 million SEATTLE and CAMBRIDGE, UK –(BUSINESS WIRE) – May 24, 2021 – Eliem Therapeutics, Inc., a
03/25/2021
SEATTLE and CAMBRIDGE, England, March 25, 2021 /PRNewswire/ — Eliem Therapeutics, Inc., a company delivering therapies that empower patients to live on their own terms, officially launched today with $80 million in financing since its inception in 2019.
Careers
We are always looking to grow our team and believe it takes teamwork, trust and tenacity to deliver on the promise of helping patients live happier, more fulfilling lives. If this sounds like you, please indicate which position you are interested in and contact us at Careers US or Careers UK.
We’d love to connect.
Contact Us
MEDIA
INVESTOR RELATIONS
HUMAN RESOURCES
PARTNERING
Eliem Therapeutics, Inc.
23515 NE Novelty Hill Road, Suite B221 #125
Redmond, WA 98053
Eliem Therapeutics (UK) Ltd: Reg. 11893311
3rd Floor, 1 Ashley Road
Altrincham, Cheshire WA14 2DT
23515 NE Novelty Hill Road, Suite B221 #125
Redmond, WA 98053
Eliem Therapeutics (UK) Ltd: Reg. 11893311
3rd Floor, 1 Ashley Road
Altrincham, Cheshire WA14 2DT